A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

Journal article

Dimitrios T Boumpas, Richard Furie, Susan Manzi, Gabor G Illei, Daniel J Wallace, James E Balow, Akshay Vaishnaw and BG9588 Lupus Nephritis Trial Grp

Arthritis and rheumatism, v 48(3), pp 719-727

Mar 2003

PMID: 12632425

Additional Links

Biological and medical sciences

Medical sciences

Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis

1 Record Views

579 citations in Scopus

Title: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
Creators: Dimitrios T Boumpas - University of Crete
Richard Furie - North Shore University Hospital
Susan Manzi - University of Pittsburgh
Gabor G Illei - National Institute of Arthritis and Musculoskeletal and Skin Diseases
Daniel J Wallace - Cedars-Sinai Medical Center
James E Balow - National Institutes of Health
Akshay Vaishnaw - Biogen
BG9588 Lupus Nephritis Trial Grp
Publication Details: Arthritis and rheumatism, v 48(3), pp 719-727
Publisher: Wiley
Number of pages: 9
Resource Type: Journal article
Language: English
Academic Unit: General Internal Medicine
Web of Science ID: WOS:000181438800019
Scopus ID: 2-s2.0-0037333857
Other Identifier: 991021934009804721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web of Science research areas: Rheumatology